The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy

Yee Chung Cheng, Gabriela Rondón, Ying Yang, Terry L. Smith, James L. Gajewski, Michele L. Donato, Elizabeth J. Shpall, Roy Jones, Gabriel N. Hortobagyi, Richard E. Champlin, Naoto T. Ueno

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk primary breast cancer patients with ≥10 positive axillary lymph nodes after primary surgery or ≥4 positive axillary lymph nodes after neoadjuvant chemotherapy and surgery. The associations of various potential prognostic factors with the relapse-free survival (RFS) rate and overall survival (OS) rate were determined. Between October 1992 and March 2000, 177 eligible patients (median age, 46 years) were given high-dose CBT followed by AHST. At a median follow-up of 63 months, the acute treatment-related mortality was 4.5%. Estimated 5-year RFS and OS rates were 62% and 68%, respectively, for all patients. For patients with ≥10 positive axillary lymph nodes after primary surgery, the 5-year RFS and OS rates were 71% and 70%, respectively, and for patients with ≥4 positive axillary lymph nodes after neoadjuvant chemotherapy, the 5-year RFS and OS rates were 53% and 66%, respectively. In 2-sided log-rank tests, earlier disease stage, a lower lymph node ratio, and a lower tumor score were associated with a prolonged RFS and OS. In a multivariate proportional hazards model, disease stage and lymph node ratio remained significant. We concluded that high-dose CBT with AHST for high-risk primary breast cancer is feasible, with comparable efficacy to other phase II studies. More than a 50% estimated 5-year survival rate was seen in all high-risk primary breast cancer patients. In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting.

Original languageEnglish (US)
Pages (from-to)794-804
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number11
DOIs
StatePublished - Nov 2004
Externally publishedYes

Keywords

  • Autologous transplantation
  • Bone marrow
  • Breast neoplasm
  • High-dose chemotherapy
  • Neoadjuvant chemotherapy
  • Peripheral blood progenitor cells

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this